Esclerosis Múltiple / Multiple Sclerosis

Volver a Principal

Instituciones Lideres en los últimos diez años ( Sólo publicaciones en la coleccion Core Clínical Journals)

Bibliografía en Revistas Internaciones de Instituciones Españolas en los últimos diez años.

 

IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D).
PLoS ONE. 2009;4(1):e4137. Epub 2009 Jan 6. Alcina A., Fedetz M., Ndagire D., Fernandez O., Leyva L., Guerrero M., Abad-Grau M.M., Arnal C., Delgado C., Lucas M., Izquierdo G., Matesanz F.

Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients' expectations?
J Neurol Sci. 2008 Oct 15;273(1-2):103-7. Epub 2008 Aug 8. Martinez-Rodriguez J.E., Munteis E., Carreno M., Blanco Y., Roquer J., Abanades S., Graus F., Saiz A.

Immunotherapy for neurological diseases.
Clin Immunol. 2008 Sep;128(3):294-305. Epub 2008 Jun 4. Villoslada P., Moreno B., Melero I., Pablos J.L., Martino G., Uccelli A., Montalban X., Avila J., Rivest S., Acarin L., Appel S., Khoury S.J., McGeer P., Ferrer I., Delgado M., Obeso J., Schwartz M.

Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways.
Mult Scler. 2009 Mar;15(3):337-44. Epub 2008 Nov 5. Sepulcre J., Masdeu J.C., Goni J., Arrondo G., Velez , Bejarano B., Villoslada P.

MR in the diagnosis and monitoring of multiple sclerosis: an overview.
Eur J Radiol. 2008 Sep;67(3):409-14. Epub 2008 Apr 22. Rovira A., Leon A.

Pharmacogenomics of multiple sclerosis: in search for a personalized therapy.
Expert Opin Pharmacother. 2008 Dec;9(17):3053-67. Martinez-Forero I., Pelaez A., Villoslada P.

Genomic regulation of CTLA4 and multiple sclerosis.
J Neuroimmunol. 2008 Oct 15;203(1):108-15. Palacios R., Comas D., Elorza J., Villoslada P.

New treatment measurements for treatment effects on relapses and progression.
J Neurol Sci. 2008 Nov 15;274(1-2):80-3. Epub 2008 Sep 25. Tintore M., Sastre-Garriga J.

Effects of resistance training in multiple sclerosis.
Int J Sports Med. 2009 Apr;30(4):245-50. Epub 2009 Feb 6. de S., Costilla S., Ayan C., Garcia-Lopez D., Gonzalez-Gallego J., de P.

A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules.
Mol Cell Neurosci. 2009 Feb;40(2):258-66. Epub 2008 Nov 19. Mestre L., Docagne F., Correa F., Loria F., Hernangomez M., Borrell J., Guaza C.

Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway.
Arch Neurol. 2009 Feb;66(2):173-9. Sepulcre J., Goni J., Masdeu J.C., Bejarano B., Velez , Toledo J.B., Villoslada P.

Cognitive dysfunction in multiple sclerosis: methods and prevalence from the GEDMA Study.
Eur Neurol. 2009;61(2):87-93. Epub 2008 Nov 28. Olazaran J., Cruz I., Benito-Leon J., Morales J.M., Duque P., Rivera-Navarro J.

Typical trigeminal neuralgia associated with brainstem white matter lesions on MRI in patients without criteria of multiple sclerosis.
Acta Neurochir (Wien). 2008 Nov;150(11):1157-61. Epub 2008 Oct 29. Arrese I., Lagares A., Alday R., Ramos A., Rivas J.J., Lobato R.D.

Plasma chitotriosidase activity in multiple sclerosis.
Clin Immunol. 2009 May;131(2):216-22. Epub 2009 Jan 26. Comabella M., Dominguez C., Rio J., Martin-Gallan P., Vilches A., Vilarrasa N., Espejo C., Montalban X.

Brain atrophy as a marker of cognitive impairment in mildly disabling relapsing-remitting multiple sclerosis.
Eur J Neurol. 2008 Oct;15(10):1091-9. Epub 2008 Aug 25. Sanchez M.P., Nieto A., Barroso J., Martin V., Hernandez M.A.

Quantitative electroencephalography reveals different physiological profiles between benign and remitting-relapsing multiple sclerosis patients.
BMC Neurol. 2008 Nov 24;8:44. Vazquez-Marrufo M., Gonzalez-Rosa J.J., Vaquero E., Duque P., Borges M., Gomez C., Izquierdo G.

Expansion of regulatory CD8+ T-lymphocytes and fall of activated CD8+ T-lymphocytes after i.v. methyl-prednisolone for multiple sclerosis relapse.
J Neuroimmunol. 2008 Nov 15;204(1-2):131-5. Aristimuno C., Navarro J., de A., Martinez-Gines L., Gimenez-Roldan S., Fernandez-Cruz E., Sanchez-Ramon S.

Memantine induces reversible neurologic impairment in patients with MS.
Neurology. 2009 May 12;72(19):1630-3. Epub 2008 Dec 17. Villoslada P., Arrondo G., Sepulcre J., Alegre M., Artieda J.

Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
Clin Immunol. 2009 Feb;130(2):145-50. Epub 2008 Oct 21. Comabella M., Rio J., Espejo C., Ruiz , Al-Zayat H., Nos C., Deisenhammer F., Baranzini S.E., Nonell L., Lopez C., Julia E., Oksenberg J.R., Montalban X.

Association between synapsin III gene promoter SNPs and multiple sclerosis in Basque patients.
Mult Scler. 2009 Jan;15(1):124-8. Epub 2008 Aug 28. Otaegui D., Zuriarrain O., Castillo-Trivino T., Aransay A., Ruiz-Martinez J., Olaskoaga J., Marti-Masso J., Lopez

Subir